ES2137628T3 - Derivados de estilbeno y composiciones farmaceuticas que los contienen. - Google Patents

Derivados de estilbeno y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2137628T3
ES2137628T3 ES96301517T ES96301517T ES2137628T3 ES 2137628 T3 ES2137628 T3 ES 2137628T3 ES 96301517 T ES96301517 T ES 96301517T ES 96301517 T ES96301517 T ES 96301517T ES 2137628 T3 ES2137628 T3 ES 2137628T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
compositions containing
derivatives
stylbene
stylbene derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96301517T
Other languages
English (en)
Inventor
Toshihiro Hatanaka
Koji Ohsumi
Takashi Tsuji
Yukio Nihei
Ryusuke Nakagawa
Kazuo Ohishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Application granted granted Critical
Publication of ES2137628T3 publication Critical patent/ES2137628T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/33—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated

Abstract

DERIVADOS DE ESTILBENO DE LA SIGUIENTE FORMULA (1) O DE SUS SALES FARMACEUTICAMENTE ACEPTABLES SON EFECTIVAS COMO CARCINOESTATICO Y DE BAJA TOXICIDAD: DONDE X REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO DE NITRILO, Y Y REPRESENTA UN GRUPO ACILO ACIDO AMINO.
ES96301517T 1995-03-07 1996-03-06 Derivados de estilbeno y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2137628T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4758195 1995-03-07

Publications (1)

Publication Number Publication Date
ES2137628T3 true ES2137628T3 (es) 1999-12-16

Family

ID=12779227

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96301517T Expired - Lifetime ES2137628T3 (es) 1995-03-07 1996-03-06 Derivados de estilbeno y composiciones farmaceuticas que los contienen.

Country Status (12)

Country Link
US (1) US5674906A (es)
EP (1) EP0731085B1 (es)
KR (1) KR100352048B1 (es)
CN (1) CN1066713C (es)
AT (1) ATE185792T1 (es)
CA (1) CA2171275C (es)
DE (1) DE69604714T2 (es)
DK (1) DK0731085T3 (es)
ES (1) ES2137628T3 (es)
GR (1) GR3032311T3 (es)
PT (1) PT731085E (es)
TW (1) TW334418B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4470321B2 (ja) * 1998-04-03 2010-06-02 味の素株式会社 抗腫瘍剤
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6624197B1 (en) 1998-05-08 2003-09-23 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6245814B1 (en) 1998-05-08 2001-06-12 Calyx Therapeutics, Inc. Diphenylethylene compounds
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6849656B1 (en) * 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20020002200A1 (en) * 2000-02-04 2002-01-03 Bishwagit Nag Novel diphenylethylene compounds
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US6525093B1 (en) * 1999-11-08 2003-02-25 Calyx Therapeutics Inc. Compounds to treat diabetes and associated conditions
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
AU4352701A (en) 2000-03-10 2001-09-24 Univ Baylor Tubulin binding ligands and corresponding prodrug constructs
CN1221527C (zh) 2000-03-17 2005-10-05 味之素株式会社 茋衍生物的新型结晶及其制造方法
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US20050153939A1 (en) * 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
JP2004517821A (ja) 2000-10-27 2004-06-17 アベンティス・ファーマ・ソシエテ・アノニム 癌治療のためのカンプトセシン及びスチルベン誘導体からなる組合せ
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
CN1543356B (zh) * 2001-06-25 2011-09-28 味之素株式会社 抗肿瘤剂
JPWO2003041740A1 (ja) * 2001-11-16 2005-03-03 味の素株式会社 腫瘍壊死剤
US6759555B2 (en) * 2002-04-11 2004-07-06 Aventis Pharma S.A. Process for the preparation of combretastatins
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
US20040063502A1 (en) * 2002-09-24 2004-04-01 Intec, Inc. Power module
US20040224768A1 (en) * 2002-09-24 2004-11-11 Saied Hussaini Video game controller with integrated status indicators
EA009048B1 (ru) 2003-02-04 2007-10-26 Кабусики Кайся Якулт Хонса Ингибитор белка резистентности рака молочной железы (bcrp)
WO2004078126A2 (en) * 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
GB2403949A (en) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Combretastatin derivatives
AU2006214164B2 (en) 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
CN1301246C (zh) * 2005-04-20 2007-02-21 江苏省原子医学研究所 1－氰基－1－(3,5－二甲氧基苯基)－2－(4－r基苯基)乙烯及其制备方法
EP1746087A1 (de) 2005-07-21 2007-01-24 Universitaet Regensburg 3-Indolylmethylen-Derivate mit cytostatischer Wirkung
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN101139358B (zh) * 2006-09-07 2011-10-12 浙江大德药业集团有限公司 乙氧基康普立停及其前药的制备和用途
BRPI0810063A2 (pt) 2007-04-20 2014-10-14 Acucela Inc Composto, composição farmacêutica, e, métodos para modular fluxo de cromóforo em um ciclo retinóide, para tratar uma doença ou distúrbio oftálmico em um indivíduo, para inibir adaptação ao escuro em uma célula fotorreceptora de bastão da retina, para inibir regeneração de rodopsina em uma célula fotoreceptora de bastão da retina, para reduzir isquemia em um olho de um indivíduo, para inibir neovascularização na retina de um olho de um indivíduo, e para inibir degeneração de uma célula da retina em uma retina
DK2219451T3 (en) 2007-11-21 2015-01-12 Oxigene Inc A method for the treatment of hematopoietic neoplasms
FR2928148B1 (fr) * 2008-02-28 2013-01-18 Sanofi Aventis Procede de preparation de combretastatine
FR2945210B1 (fr) 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
FR2953518B1 (fr) 2009-12-03 2012-01-20 Sanofi Aventis Procede de preparation d'un derive de combretastatine
WO2011151423A1 (en) 2010-06-04 2011-12-08 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
EP2481404A1 (en) 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2397135A1 (en) 2010-06-18 2011-12-21 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
SG186376A1 (en) 2010-06-18 2013-01-30 Sanofi Sa An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2407161A1 (en) 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
FR2968557A1 (fr) 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
EP2673250B1 (en) * 2011-01-28 2016-11-23 University of Kentucky Research Foundation Stilbene analogs and methods of treating cancer
CN102863388B (zh) 2011-07-05 2015-04-29 南京圣和药业股份有限公司 肿瘤靶向药物Combretastatin A4衍生物
WO2013084150A1 (en) * 2011-12-06 2013-06-13 Sanofi Novel crystal form of (2s)-2-amino-3-hydroxy-n-[2-methoxy-2-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide and method of preparation thereof
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN103012248B (zh) * 2013-01-11 2014-11-05 浙江大德药业集团有限公司 氨基康普立停衍生物的合成及其作为口服抗肿瘤药物的应用
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
US9458086B1 (en) 2013-07-03 2016-10-04 University Of South Florida (A Florida Non-Profit Corporation) Compositions and methods for adipocyte modulation
BR112016017997A2 (pt) 2014-02-03 2017-08-08 Quadriga Biosciences Inc Beta aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos
CN106132406B (zh) 2014-02-03 2020-03-27 夸德里加生物科学公司 作为化疗剂的β-取代的γ-氨基酸和类似物
US9487482B2 (en) * 2014-05-09 2016-11-08 Council Of Scientific And Industrial Research 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents
TWI665178B (zh) 2015-08-03 2019-07-11 夸德里加生物科學公司 作為化療劑的β－取代的β－氨基酸和類似物及其應用
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CN112225673B (zh) * 2020-11-13 2022-08-02 义乌市华耀医药科技有限公司 氨基康普立停衍生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL250327A (es) * 1959-04-08
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
AU4385293A (en) 1992-05-21 1993-12-13 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
JP3180127B2 (ja) * 1993-03-10 2001-06-25 森永乳業株式会社 スチルベン誘導体とスチルベン同族体誘導体及びそれらの用途
TW325458B (en) * 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer

Also Published As

Publication number Publication date
ATE185792T1 (de) 1999-11-15
CA2171275A1 (en) 1996-09-08
CA2171275C (en) 2005-12-20
PT731085E (pt) 2000-04-28
DE69604714D1 (de) 1999-11-25
TW334418B (en) 1998-06-21
KR960034164A (ko) 1996-10-22
US5674906A (en) 1997-10-07
DK0731085T3 (da) 2000-04-17
KR100352048B1 (ko) 2003-05-12
DE69604714T2 (de) 2000-06-15
EP0731085B1 (en) 1999-10-20
EP0731085A1 (en) 1996-09-11
CN1066713C (zh) 2001-06-06
GR3032311T3 (en) 2000-04-27
CN1143629A (zh) 1997-02-26

Similar Documents

Publication Publication Date Title
ES2137628T3 (es) Derivados de estilbeno y composiciones farmaceuticas que los contienen.
TR200101969T2 (tr) Enflamasyon tedavisi için sübstitüe edilmiş benzopiran analogları.
MX9305769A (es) Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
IT1283588B1 (it) Miscela sinergica di agenti stabilizzanti
IL135333A0 (en) Acylsulfamoyl benzoic acid amides, plant protection agents containing said acylsulfamoyl benzoic acid amides, and method for producing the same
ES2179823T3 (es) Inmunosupresor macrolido.
ES2161290T3 (es) Derivados de quinazolina.
ES2142798T3 (es) Derivados de 3-amido pirazol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
ES2104090T3 (es) Nuevas 3',5'-di-t-butil-4'-hidroxi-flavonas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2128519T3 (es) Nuevas pirido-tiadiazinas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
NO954768D0 (no) N-alkyltiopolyaminderivater som radiobeskyttende midler
ES2108422T3 (es) Combinaciones sinergicas de productos antisolares y composiciones cosmeticas y dermatologicas que las contienen.
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
ES2056153T3 (es) Expectorante que comprende un derivado hidroxialquilcisteina.
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
ES2160308T3 (es) Nuevos derivados amino-metil-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2125963T3 (es) Nuevos derivados espiranicos del 3-amino-cromano, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
ES2052522T3 (es) Derivados de pirimidina, su preparacion y medicamentos que los contienen.
DK0452204T3 (da) Hidtil ukendte 3-aminochromanderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2182090T3 (es) Nuevos derivados de pirrol.
ES2003063A4 (es) Derivados de pirrolidin-2-ona, que tengan actividad nootropica.
ES2095431T3 (es) N-(isoquinolein-5-il)-sulfonil-azacicloalcanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 731085

Country of ref document: ES